ALVO Alvotech

USD 14.39 -0.07 -0.484094
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 14.39

-0.07 (-0.48)%

USD 4.04B

0.09M

USD 21.80(+51.49%)

USD 12.00 (-16.61%)

Icon

ALVO

Alvotech (USD)
COMMON STOCK | NSD
USD 14.39
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 4.04B

USD 12.00 (-16.61%)

USD 14.39

Alvotech (ALVO) Stock Forecast

USD 21.80
(+51.49%)

Based on the Alvotech stock forecast from 2 analysts, the average analyst target price for Alvotech is USD 21.80 over the next 12 months. Alvotech’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alvotech is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Alvotech’s stock price was USD 14.39. Alvotech’s stock price has changed by +3.45% over the past week, +7.63% over the past month and +75.49% over the last year.

No recent analyst target price found for Alvotech
No recent average analyst rating found for Alvotech

Company Overview Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration f...Read More

https://www.alvotech.com

Saemundargata 15-19, Reykjavik, Iceland, 102

999

December

USD

USA

Adjusted Closing Price for Alvotech (ALVO)

Loading...

Unadjusted Closing Price for Alvotech (ALVO)

Loading...

Share Trading Volume for Alvotech Shares

Loading...

Compare Performance of Alvotech Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ALVO

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Alvotech (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NBIX
Neurocrine Biosciences Inc -1.55 (-1.15%) USD13.58B 36.68 36.15

ETFs Containing ALVO

Symbol Name ALVO's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Alvotech (ALVO) Stock

Based on ratings from 2 analysts Alvotech's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 5 buy, sell and hold ratings.

Unfortunately we do not have enough data on ALVO's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for ALVO is USD 21.80 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 17.

ALVO stock's Price/Earning ratio is 55.96. Our analysis grades ALVO stock's Price / Earning ratio at F. This means that ALVO stock's Price/Earning ratio is above 71% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange. Based on this ALVO may be a overvalued for its sector.

The last closing price of ALVO's stock was USD 14.39.

The most recent market capitalization for ALVO is USD 4.04B.

Based on targets from 2 analysts, the average taret price for ALVO is projected at USD 21.80 over the next 12 months. This means that ALVO's stock price may go up by +51.49% over the next 12 months.

We can't find any ETFs which contains Alvotech's stock.

As per our most recent records Alvotech has 999 Employees.

Alvotech's registered address is Saemundargata 15-19, Reykjavik, Iceland, 102. You can get more information about it from Alvotech's website at https://www.alvotech.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...